Related Experiment Videos
Trimethoprim-sulfamethoxazole in murine toxoplasmosis
Antimicrobial Agents and Chemotherapy
|February 1, 1976
Abstract:
The combination trimethoprim-sulfamethoxazole had no greater activity in a murine model of toxoplasmosis than did sulfamethoxazole alone.
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Evaluation of the immunoglobulin G avidity test for diagnosis of toxoplasmic lymphadenopathy.
Journal of clinical microbiology·2004
Effect of moxifloxacin on secretion of cytokines by human monocytes stimulated with lipopolysaccharide.
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases·2002
Infectious complications among 620 consecutive heart transplant patients at Stanford University Medical Center.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2001
Effect of testing for IgG avidity in the diagnosis of Toxoplasma gondii infection in pregnant women: experience in a US reference laboratory.
The Journal of infectious diseases·2001
Confirmatory serologic testing for acute toxoplasmosis and rate of induced abortions among women reported to have positive Toxoplasma immunoglobulin M antibody titers.
American journal of obstetrics and gynecology·2001
Impact of renal impairment on pharmacokinetics, safety, and tolerability of funobactam, combined with imipenem and cilastatin.
Antimicrobial agents and chemotherapy·2026
Training a phage to expand its host range: directed evolution against Staphylococcus aureus from diabetic foot infections.
Antimicrobial agents and chemotherapy·2026
IS26-mediated circular blaKPC transposon in ST2483 Pseudomonas aeruginosa.
Antimicrobial agents and chemotherapy·2026
A chloramine-based antiseptic polymer improves Candida auris skin decolonization compared to chlorhexidine in a murine model.
Antimicrobial agents and chemotherapy·2026
In vivo emergence of ceftazidime/avibactam resistance in Pseudomonas aeruginosa driven by OXA-1381, a novel W157L Ω-loop variant of OXA-2.
Antimicrobial agents and chemotherapy·2026